LivaNova Quote - LIVN

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

41.70

Bid

41.00

Ask

71.50

Volume

2,800,497

40.51 Day's Range 47.485

41.70 52 Week Range 64.475

Market Cap

2.264B

Previous Close

49.50

Open

46.89

Last Trade

Last Trade Time

Financial Volume

US$ 117,504,415

VWAP

41.9584

Average Volume (3m)

501,862

Shares Outstanding

54,300,835

Dividend Yield

PE Ratio

127.98

Earnings Per Share (EPS)

0.33

Revenue

1.15B

Net Profit

17.75M

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. Our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients healthcare prof... LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. Our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients healthcare professionals and healthcare systems. At LivaNova we understand the importance of bringing both clinical and economic value to our customers. We are a strong market-leading medical technology and services company offering a diverse product portfolio and global reach. LivaNova is listed on the NASDAQ stock exchange under the ticker symbol LIVN. LivaNova has approximately 3000 employees worldwide. We are headquartered in London UK and maintain a presence in more than 100 countries. LivaNova is a worldwide leader in advanced circulatory support cardiopulmonary and neuromodulation dedicated to creating meaningful products and therapies that transform lives each and every day. Show more

Sector

Electromedical Apparatus

Industry

Electromedical Apparatus

Website

www.livanova.com

Headquarters

London, Gbr

Founded

LivaNova PLC is listed in the Electromedical Apparatus sector of the NASDAQ with ticker LIVN. The last closing price for LivaNova was US$49.50. Over the last year, LivaNova shares have traded in a share price range of US$ 41.70 to US$ 64.475.

LivaNova currently has 54,300,835 shares outstanding. The market capitalization of LivaNova is US$2.69 billion. LivaNova has a price to earnings ratio (PE ratio) of 127.98.

Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

Results published in two articles in Brain Stimulation LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-5.88	-12.3581336696	47.58	49.795	41.7	669046	48.34156276	CS
4	-8.05	-16.1809045226	49.75	52.08	41.7	468039	48.6585172	CS
12	-10.39	-19.9462468804	52.09	52.7	41.7	501862	48.74709333	CS
26	-5.37	-11.4085404716	47.07	57.29	41.7	484245	50.04371688	CS
52	-15.16	-26.6619767851	56.86	64.475	41.7	606913	52.31574788	CS
156	-36.54	-46.7024539877	78.24	88	40.26	495525	53.43887134	CS
260	-27.2	-39.4775036284	68.9	93.89	33.4	484332	57.79618525	CS

LIVN - Frequently Asked Questions (FAQ)

What is the current LivaNova share price?

The current share price of LivaNova is US$ 41.70

How many LivaNova shares are in issue?

LivaNova has 54,300,835 shares in issue

What is the market cap of LivaNova?

The market capitalisation of LivaNova is USD 2.69B

What is the 1 year trading range for LivaNova share price?

LivaNova has traded in the range of US$ 41.70 to US$ 64.475 during the past year

What is the PE ratio of LivaNova?

The price to earnings ratio of LivaNova is 127.98

What is the cash to sales ratio of LivaNova?

The cash to sales ratio of LivaNova is 1.97

What is the reporting currency for LivaNova?

LivaNova reports financial results in USD

What is the latest annual turnover for LivaNova?

The latest annual turnover of LivaNova is USD 1.15B

What is the latest annual profit for LivaNova?

The latest annual profit of LivaNova is USD 17.75M

What is the registered address of LivaNova?

The registered address for LivaNova is 20 EASTBOURNE TERRACE, NORTH WHARF ROAD, LONDON, W2 6LG

What is the LivaNova website address?

The website address for LivaNova is www.livanova.com

Which industry sector does LivaNova operate in?

LivaNova operates in the ELECTROMEDICAL APPARATUS sector

Symbol	Price	Vol.
ONVOOrganovo Holdings Inc	US$ 1.2502 (238.81%)	381.24M
RETOReTo Eco Solutions Inc	US$ 1.065 (80.51%)	78.63M
VEROVenus Concept Inc	US$ 0.5402 (76.54%)	15.55M
SLXNSilexion Therapeutics Corporation	US$ 1.23 (64.00%)	87.34M
WAFUWah Fu Education Group Ltd	US$ 2.825 (57.82%)	124.95M
YYAIConnexa Sports Technologies Inc	US$ 0.681 (-46.38%)	6.22M
RNAZTransCode Therapeutics Inc	US$ 4.34 (-35.99%)	611.44k
ACONAclarion Inc	US$ 3.25 (-30.26%)	417.53k
BTDRBitdeer Technologies Group	US$ 9.255 (-29.35%)	16.96M
NKLANikola Corporation	US$ 0.184 (-28.35%)	37.07M
ONVOOrganovo Holdings Inc	US$ 1.2502 (238.81%)	386.3M
NVDANVIDIA Corporation	US$ 126.63 (-2.80%)	271.57M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 14.41 (-16.85%)	167.52M
SMCISuper Micro Computer Inc	US$ 45.54 (-11.76%)	146.57M
TSLATesla Inc	US$ 302.80 (-8.39%)	134.25M

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

LivaNova PLC (LIVN) Share Price

LivaNova PLC (LIVN)

Professional-Grade Tools, for Individual Investors.

Key stats and details

About LivaNova PLC

Ask ADVFN Intelligence (AI)

LIVN Latest News

Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

LivaNova to Present at the Barclays Global Healthcare Conference

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

Form 3 - Initial statement of beneficial ownership of securities

LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

Form 4 - Statement of changes in beneficial ownership of securities

Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

LivaNova to Present at the Barclays Global Healthcare Conference

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

Form 3 - Initial statement of beneficial ownership of securities

LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

LIVN - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free